CDMO News
Exothera to Develop and Manufacture Asgard Therapeutics’ AT-108 Gene Therapy
Asgard Therapeutics, a biotech company specialising in in vivo direct cell reprogramming for cancer immunotherapy, has announced its selection of Exothera S.A. for the process development and clinical Phases I/II manufacturing of its candidate AT-108. The candidate is based on
11 June 2024